Ashraf Ibrahim, Ph.D., principal investigator at LA BioMed who specializes in infectious diseases, was recently honored by the American Society for Microbiology (ASM) and the ICAAC Program Committee in the area of Therapy and Prevention of Microbial Disease. The Program Committee Award presented by ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) recognizes Dr. Ibrahim's work with Acinetobacter baumannii, as outlined in an abstract entitled "Murine Inhalational Pneumonia Models of Acinetobacter baumannii: Colistin Versus Impenem Therapy." Dr. Ibrahim will be honored at the conference which is being held Sept. 17-20, 2011 in Chicago, Ill., the site of the 51st annual ICAAC.
Dr. Ibrahim is studying the severity of and therapeutic interventions against A. baumannii, which has emerged as one of the most common and highly antibiotic-resistant causes of infection. A. baumannii infections in patients with cancer or neutropenia have widely been described, with diabetes posing as a risk factor for the acquisition of, and worse outcomes, from A. baumannii infection.
"We congratulate Dr. Ibrahim on this well-deserved honor and prestigious award," said David I. Meyer, Ph.D., President and CEO of LA BioMed. "To be singled out among so many in his field is a testament to the vital contributions Dr. Ibrahim has made, and continues to make, in the area of infectious diseases."
Annual COVID-19 vaccine proves to be a wise investment for personal health and pocketbook